In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, highlights key findings from ...

Welireg (belzutifan), an oral HIF-2α inhibitor, demonstrated an objective response rate of 26% in the LITESPARK-015 study. 1. Regulatory milestone for rare tumors: Merck’s Welireg received FDA ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

Upping the Migraine Intelligence Quotient: RWD sheds light on prevalence rates, providers and treatment variation ...

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug ...

In this video interview, Michael Liu, medical student and researcher at Harvard Medical School, discusses a recent study he conducted on the characterization of research funding cuts.

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...